1.Circulatory endostatin level and risk of cardiovascular events in patients with end-stage renal disease on hemodialysis
Jin Sug KIM ; Miji KIM ; Kyung Hwan JEONG ; Ju-Young MOON ; Sang Ho LEE ; Gang Jee KO ; Dong-Young LEE ; So Young LEE ; Yang Gyun KIM ; Hyeon Seok HWANG
Kidney Research and Clinical Practice 2024;43(2):226-235
Endostatin is released during extracellular matrix remodeling and is involved in the development of vascular pathology and cardiovascular (CV) disease. However, the role of circulating endostatin as a biomarker of vascular calcification and CV events in patients undergoing hemodialysis (HD) remains unclear. Methods: A total of 372 patients undergoing HD were prospectively recruited. Plasma endostatin levels were measured at baseline, and their associations with circulating mineral bone disease (MBD) biomarkers and abdominal aortic vascular calcification scores were analyzed. The primary endpoint was defined as a composite of CV and cardiac events. Results: Plasma levels of patients in endostatin tertile 3 were significantly associated with low-density lipoprotein cholesterol levels and predialysis systolic blood pressure in multivariate analysis. However, endostatin levels did not correlate with circulating MBD biomarkers or vascular calcification scores. Patients in endostatin tertile 3 had a significantly higher cumulative event rate for the composite of CV events (p = 0.006). Endostatin tertile 3 was also associated with an increased cumulative rate of cardiac events (p = 0.04). In multivariate Cox regression analyses, endostatin tertile 3 was associated with a 4.37-fold risk for composite CV events and a 3.88-fold risk for cardiac events after adjusting for multiple variables. Conclusion: Higher circulating endostatin levels were independently associated with atherosclerotic risk factors but did not correlate with MBD markers or vascular calcification. Higher circulating endostatin levels were associated with a greater risk of composite CV events in patients undergoing HD, and endostatin is a biomarker that helps to determine the high risk of CV events.
2.Analysis of the Switching Patterns of Biologics and Their Efficacy after Switching in Moderate-to-Severe Psoriasis Patients
Su Min LEE ; Byeong Chang KO ; Sang Woo AHN ; Ji An UH ; Jung Eun SEOL ; Hyojin KIM ; Soo Kyung LEE ; Myoung Shin KIM ; Un Ha LEE ; So Hee PARK ; So Young JUNG ; Hai-Jin PARK
Korean Journal of Dermatology 2022;60(7):420-428
Background:
Biologics-experienced patients are more likely to show a lower response to biologics than that of biologic-naïve patients. However, no consensus on switching biologics exists.
Objective:
We aimed to investigate the switching patterns and efficacy of the switched biologics in patients with moderate-to-severe psoriasis in actual clinical practice.
Methods:
This multicenter retrospective study included 37 patients with a history of switching biologics. We analyzed the reasons for switching, the switching patterns, and psoriasis area and severity index (PASI) 75 response rates after switching biologics. We also analyzed the factors affecting the PASI75 response rate to the second biologic.
Results:
The reasons for switching baseline biologics were primary failure in five patients (13.5%), secondary failure in 28 patients (75.7%), and adverse events in four patients (10.8%). The second biologics prescribed mostly include interleukin (IL)-23 inhibitor in twenty-four patients (64.9%), IL-17 inhibitor in eight patients (21.6%), tumor necrosis factor-α inhibitor in three patients (8.1%), and IL-12/23 inhibitor in two patients (5.4%). A total of 46% of patients (17/37) switched biologics from IL-12/23 inhibitors to IL-23 inhibitors. The PASI75 response rates at the primary endpoint of the second and third biologics were 89.2% and 88.8%, respectively. Our study found that female sex and obesity were associated with the primary failure of the second biologic.
Conclusion
Secondary failure was the most common reason for switching baseline biologics. Korean dermatologists prefer different classes of biologics while switching. The PASI75 response rates at the primary endpoints of the second and third biologics were relatively satisfactory.
3.Diallyl Biphenyl-Type Neolignans Have a Pharmacophore of PPARα/γ Dual Modulators
Yujia HAN ; Jingjing LIU ; Sungjin AHN ; Seungchan AN ; Hyejin KO ; Jeayoung C. SHIN ; Sun Hee JIN ; Min Won KI ; So Hun LEE ; Kang Hyuk LEE ; Song Seok SHIN ; Won Jun CHOI ; Minsoo NOH
Biomolecules & Therapeutics 2020;28(5):397-404
Adiponectin secretion-promoting compounds have therapeutic potentials in human metabolic diseases. Diallyl biphenyl-type neolignan compounds, magnolol, honokiol, and 4-O-methylhonokiol, from a Magnolia officinalis extract were screened as adiponectin-secretion promoting compounds in the adipogenic differentiation model of human bone marrow mesenchymal stem cells (hBM-MSCs). In a target identification study, magnolol, honokiol, and 4-O-methylhonokiol were elucidated as PPARα and PPARγ dual modulators. Diallyl biphenyl-type neolignans affected the transcription of lipid metabolism-associated genes in a different way compared to those of specific PPAR ligands. The diallyl biphenyl-type neolignan structure provides a novel pharmacophore of PPARα/γ dual modulators, which may have unique therapeutic potentials in diverse metabolic diseases.
4.Psychosocial Support during the COVID-19 Outbreak in Korea: Activities of Multidisciplinary Mental Health Professionals
Jinhee HYUN ; Sungeun YOU ; Sunju SOHN ; Seok-Joo KIM ; Jeongyee BAE ; Myungjae BAIK ; In Hee CHO ; Hyunjung CHOI ; Kyeong-Sook CHOI ; Chan-Seung CHUNG ; Chanyoung JEONG ; Hyesun JOO ; Eunji KIM ; Heeguk KIM ; Hyun Soo KIM ; Jinsun KO ; Jung Hyun LEE ; Sang Min LEE ; So Hee LEE ; Un Sun CHUNG
Journal of Korean Medical Science 2020;35(22):e211-
As of April 18, 2020, there have been a total of 10,653 confirmed cases and 232 deaths due to coronavirus disease 2019 (COVID-19) in Korea. The pathogen spread quickly, and the outbreak caused nationwide anxiety and shock. This study presented the anecdotal records that provided a detailed process of the multidisciplinary teamwork in mental health during the COVID-19 outbreak in the country. Psychosocial support is no less important than infection control during an epidemic, and collaboration and networking are at the core of disaster management. Thus, a multidisciplinary team of mental health professionals was immediately established and has collaborated effectively with its internal and external stakeholders for psychosocial support during the COVID-19 outbreak.
5.Artificial Intelligence in Health Care: Current Applications and Issues
Chan-Woo PARK ; Sung Wook SEO ; Noeul KANG ; Beom Seok KO ; Byung Wook CHOI ; Chang Min PARK ; Dong Kyung CHANG ; Hwiuoung KIM ; Hyun chul KIM ; Hyun na LEE ; Jin hee JANG ; Jong Chul YE ; Jong Hong JEON ; Joon Beom SEO ; Kwang Joon KIM ; Kyu-Hwan JUNG ; Namkug KIM ; Seung wook PAEK ; Soo-Yong SHIN ; So young YOO ; Yoon Sup CHOI ; Youngjun KIM ; Hyung-Jin YOON
Journal of Korean Medical Science 2020;35(42):e379-
In recent years, artificial intelligence (AI) technologies have greatly advanced and become a reality in many areas of our daily lives. In the health care field, numerous efforts are being made to implement the AI technology for practical medical treatments. With the rapid developments in machine learning algorithms and improvements in hardware performances, the AI technology is expected to play an important role in effectively analyzing and utilizing extensive amounts of health and medical data. However, the AI technology has various unique characteristics that are different from the existing health care technologies. Subsequently, there are a number of areas that need to be supplemented within the current health care system for the AI to be utilized more effectively and frequently in health care. In addition, the number of medical practitioners and public that accept AI in the health care is still low;moreover, there are various concerns regarding the safety and reliability of AI technologyimplementations. Therefore, this paper aims to introduce the current research and application status of AI technology in health care and discuss the issues that need to be resolved.
6.Prevalence of Tarsal Coalition in the Korean Population: A Single Institution-Based Study
Tae Yong KIM ; So Hee YOON ; Jung Hoon KO ; Tae Ho LEE ; Seung Rim YI
The Journal of the Korean Orthopaedic Association 2020;55(4):324-330
Purpose:
Korean studies on the prevalence of a tarsal coalition are quite rare, and there are very few reports on the prevalence of multipletarsal coalitions among adults in the foreign literature. Therefore, this study examined the characteristics and prevalence of tarsal coalitionin the Korean population based on imaging tests.
Materials and Methods:
The prevalence of tarsal coalition and its anatomical location and histological classification were reviewedretrospectively among 4,711 patients (4,454 males and 257 females) with an ankle sprain or ankle fracture who underwent foot and anklecomputed tomography and magnetic resonance imaging between March 2009 and February 2019 at the authors’ institution.
Results:
Over a period of 10 years, 78 patients (1.7%) had a tarsal coalition, among whom 53 patients (67.9%) had an isolated tarsalcoalition and 25 patients (32.1%) had multiple tarsal coalitions. Regarding the anatomical location, a talocalcaneal coalition was the mostcommon type in both isolated (31 patients, 37 cases [62.7%]) and multiple (22 patients, 23 cases [45.1%]) tarsal coalitions. In the isolatedcoalition group, the second-most common type was calcaneonavicular coalition (10 patients, 16.9%), followed by naviculocuneiform (ninepatients, 15.3%) and cuboidonavicular coalitions (three patients, 5.1%). In the multiple coalition group, the second-most common coalitiontype was calcaneonavicular coalition (14 patients, 14 cases [27.5%]), followed by talonavicular coalition (six patients, six cases [11.8%]).From a total of 60 cases of talocalcaneal coalition, 24 cases (40.0%) were in the posterior facet, 18 cases (30.0%) in the middle facet, andfour cases (6.7%) in the anterior facet. Regarding the histological classification, cartilaginous coalition was the most common in both single(32 patients, 35 cases [59.3%]) and multiple (20 patients, 37 cases [72.5%]) coalition groups.
Conclusion
The present study found that talocalcaneal coalition was the most common type of tarsal coalition. In contrast to previousreports that a talocalcaneal coalition generally occurs in the middle facet, it was usually observed in the posterior facet in the presentstudy. In addition, although multiple tarsal coalitions have been reported to be quite rare, this study confirmed that they are not rare andcan occur in a range of patterns.
7.Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.
Jin Won KIM ; Jong Gwang KIM ; Byung Woog KANG ; Ik Joo CHUNG ; Young Seon HONG ; Tae You KIM ; Hong Suk SONG ; Kyung Hee LEE ; Dae Young ZANG ; Yoon Ho KO ; Eun Kee SONG ; Jin Ho BAEK ; Dong‐Hoe KOO ; So Yeon OH ; Hana CHO ; Keun Wook LEE
Cancer Research and Treatment 2019;51(1):223-239
PURPOSE: The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC). MATERIALS AND METHODS: Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians. RESULTS: Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients' QOL was maintained to a similar degree, regardless of their actual response to chemotherapy. CONCLUSION: This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.
Disease-Free Survival
;
Drug Therapy*
;
Drug Therapy, Combination
;
Global Health
;
Humans
;
Korea
;
Observational Study
;
Prospective Studies
;
Quality of Life*
;
Stomach Neoplasms*
;
Weights and Measures
8.Determining the Reliability of a New Method for Measuring Joint Range of Motion Through a Randomized Controlled Trial
So Young AHN ; Hanbit KO ; Jeong Oh YOON ; Sun Ung CHO ; Jong Hyun PARK ; Kang Hee CHO
Annals of Rehabilitation Medicine 2019;43(6):707-719
OBJECTIVE: To compare the reliability and validity of the Korean range of motion standard protocol (KRSP) for measuring joint range of motion (ROM) with those of the conventional ROM measurement using a goniometer.METHODS: We conducted a randomized controlled trial involving 91 healthy elderly individuals. We compared two strategies of measuring joint ROM to evaluate the reliability and validity of each standardized protocol: first, the KRSP based on the Chungnam National University guidelines and second, handheld goniometric measurement. In the first strategy, 3 examiners (1 rehabilitation doctor, 1 physical therapist, and 1 physical therapy student) independently measured joint ROM in 46 randomly selected subjects; in the second strategy, another 3 examiners (1 rehabilitation doctor, 1 physical therapist, and 1 physical therapy student) measured joint ROM in 45 randomly selected subjects. The reliability of each protocol was calculated using intraclass correlation coefficient, ICC(2,1), and root mean square error (RMSE).RESULTS: Both protocols showed good to excellent intra-rater reliability. With goniometer use, the inter-rater reliability was low—ICC(2,1), 95% confidence interval ranged from 0.643 (0.486–0.783) to -0.078 (-0.296–0.494)— and RMSE was high. With the KRSP, the inter-rater reliability ranged from 0.846 (0.686–0.931) to 0.986 (0.972–0.994) and RMSE was low.CONCLUSION: ROM measurements using the KRSP showed excellent reliability. These results indicate that this protocol can be the reference standard for measuring ROM in clinical settings as an alternative to goniometers.
Aged
;
Chungcheongnam-do
;
Humans
;
Joints
;
Methods
;
Physical Therapists
;
Range of Motion, Articular
;
Rehabilitation
;
Reproducibility of Results
9.Effect of a Deep Learning Framework-Based Computer-Aided Diagnosis System on the Diagnostic Performance of Radiologists in Differentiating between Malignant and Benign Masses on Breast Ultrasonography
Ji Soo CHOI ; Boo Kyung HAN ; Eun Sook KO ; Jung Min BAE ; Eun Young KO ; So Hee SONG ; Mi ri KWON ; Jung Hee SHIN ; Soo Yeon HAHN
Korean Journal of Radiology 2019;20(5):749-758
OBJECTIVE: To investigate whether a computer-aided diagnosis (CAD) system based on a deep learning framework (deep learning-based CAD) improves the diagnostic performance of radiologists in differentiating between malignant and benign masses on breast ultrasound (US). MATERIALS AND METHODS: B-mode US images were prospectively obtained for 253 breast masses (173 benign, 80 malignant) in 226 consecutive patients. Breast mass US findings were retrospectively analyzed by deep learning-based CAD and four radiologists. In predicting malignancy, the CAD results were dichotomized (possibly benign vs. possibly malignant). The radiologists independently assessed Breast Imaging Reporting and Data System final assessments for two datasets (US images alone or with CAD). For each dataset, the radiologists' final assessments were classified as positive (category 4a or higher) and negative (category 3 or lower). The diagnostic performances of the radiologists for the two datasets (US alone vs. US with CAD) were compared. RESULTS: When the CAD results were added to the US images, the radiologists showed significant improvement in specificity (range of all radiologists for US alone vs. US with CAD: 72.8–92.5% vs. 82.1–93.1%; p < 0.001), accuracy (77.9–88.9% vs. 86.2–90.9%; p = 0.038), and positive predictive value (PPV) (60.2–83.3% vs. 70.4–85.2%; p = 0.001). However, there were no significant changes in sensitivity (81.3–88.8% vs. 86.3–95.0%; p = 0.120) and negative predictive value (91.4–93.5% vs. 92.9–97.3%; p = 0.259). CONCLUSION: Deep learning-based CAD could improve radiologists' diagnostic performance by increasing their specificity, accuracy, and PPV in differentiating between malignant and benign masses on breast US.
Breast
;
Dataset
;
Diagnosis
;
Humans
;
Information Systems
;
Learning
;
Prospective Studies
;
Retrospective Studies
;
Sensitivity and Specificity
;
Ultrasonography
;
Ultrasonography, Mammary
10.Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.
Hee Yeon SEO ; Han Ah LEE ; Soon Young KO ; Joon Ho WANG ; Jeong Han KIM ; Won Hyeok CHOE ; So Young KWON
Clinical and Molecular Hepatology 2017;23(2):154-159
BACKGROUND/AIMS: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-naive patients with CHB during long-term TDF monotherapy. METHODS: One hundred eighty-one treatment-naive CHB patients were treated with a 300-mg once-daily dose of TDF for more than 12 weeks. Virological markers of hepatitis B virus (HBV) and biochemical data were measured at baseline and every 4-12 weeks during the therapy. The proportion of patients with undetectable HBV DNA level (< 100 copies/mL) was noted. RESULTS: The median age was 48.3 years and 122 patients (67.4%) were men. Hepatitis B envelope antigen (HBeAg) was positive in 101 patients (55.8%). No patient had cirrhosis. The median follow-up duration was 45 weeks (12-155 weeks). ALT flare (>5 × upper limit of the normal range) occurred in seven patients (3%) without viral breakthrough within the first 8 weeks after the start of TDF monotherapy. Among them, six patients were HBeAg-positive and one patient was HBeAg-negative. All cases of early ALT flares resolved within 4 weeks and virologic response was observed in all patients without interruption or discontinuation of treatment. CONCLUSIONS: Continuous TDF monotherapy was effective and safe in treatment-naive patients with CHB who experienced early ALT flares followed by a decrease in HBV DNA level.
Alanine Transaminase
;
Alanine*
;
DNA
;
Fibrosis
;
Follow-Up Studies
;
Hepatitis B
;
Hepatitis B virus
;
Hepatitis B, Chronic*
;
Hepatitis, Chronic*
;
Humans
;
Incidence
;
Male
;
Tenofovir*

Result Analysis
Print
Save
E-mail